Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Teva Pharma target lowered to $40 at Maxim Group following earnings (33.98 +1.79)Maxim Group lowers their TEVA tgt to $40 from $41 following Q4 results. Firm continues to watch Copaxone market share which today they est accounts for 28%-29% of new and total Rx's in the U.S. Firm models additional share loss not yet factored into Teva's guidance; however their numbers are in-line with guidance as they assume more robust performance in generics performance; Hold.</td> </tr></table>"